- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 | 1 | GlobeNewswire (USA) | ||
| 24.04. | BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals | 1 | Alliance News | ||
| 23.04. | Tarsus refinances existing debt with $200M financing commitment | 1 | Seeking Alpha | ||
| 23.04. | Tarsus Pharmaceuticals, Inc: Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon | 1 | GlobeNewswire (USA) | ||
| 23.04. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.03. | Tarsus Pharmaceuticals CCO sells shares worth over $145k | 2 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals CEO sells shares worth over $318k | 1 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals executive sells over $130k in company stock | 1 | Investing.com | ||
| 20.03. | Tarsus Pharmaceuticals exec sells over $135k in stock | 1 | Investing.com | ||
| 12.03. | Tarsus launches a 'Mite Party' for new Xdemvy marketing campaign | 2 | FiercePharma | ||
| 06.03. | Jefferies raises Tarsus Pharma stock target to $44 on strong launch | 1 | Investing.com | ||
| 05.03. | Tarsus Pharmaceuticals, Inc: Tarsus to Participate at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 05.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Tarsus Pharmaceuticals, Inc: Tarsus Introduces "Mite Party" Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis | 120 | GlobeNewswire (Europe) | Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately... ► Artikel lesen | |
| 04.03. | Tarsus Redefines Financial Strategy by Combining Innovative Outsourced Accounting, CFO, Finance, and Transaction Services | 339 | ACCESSWIRE | WASHINGTON, DC / ACCESSWIRE / March 4, 2024 / Tarsus, a trailblazing accounting, financial, and transaction services firm, is proud to announce its official re-branding and expanding industry and service... ► Artikel lesen | |
| 01.03. | Tarsus Pharma slides on $100 million stock offering | 1 | Reuters | ||
| 01.03. | Tarsus Pharmaceuticals sets $32 stock offering price | 1 | Investing.com | ||
| 01.03. | Tarsus Pharmaceuticals stock dips after pricing $100M securities offering | 1 | Seeking Alpha | ||
| 01.03. | Tarsus Pharmaceuticals, Inc: Tarsus Announces Pricing of $100.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 29.02. | Tarsus Pharmaceuticals launches $100 million stock offering | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -1,27 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,095 | +34,19 % | EQS-News: Defence Therapeutics Inc.: Pankreaskrebs: Erfolgreicher Test zur Bekämpfung von Pankreaskrebs mit dem ARM-002-Impfstoff von Defence | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,848 | +0,69 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,890 | +5,29 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,580 | +2,88 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,070 | +3,88 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,550 | -4,84 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,000 | +9,41 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,330 | +0,11 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | +0,17 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,070 | +3,66 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,170 | +3,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,360 | +0,32 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,590 | -3,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,010 | +3,80 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,31 % bei einem Aktienkurs von 33,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
